PO.CL01.12 · 临床研究

具有极端临床结局的原发性黑色素瘤的空间转录组学分析

Spatial transcriptomic analysis of primary melanomas with extreme clinical outcomes

海报缩略图:具有极端临床结局的原发性黑色素瘤的空间转录组学分析
编号 1215 展板 16 时间 4/19 02:00–05:00 区域 Section 47 主讲 Prachi Bhave, BE;MBBS
分会场 Spatial Proteomics and Transcriptomics 1
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Prachi Bhave1, Marie Trussart2, Anthony T. Papenfuss2, Grant A. McArthur3

1The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia,2Walter & Eliza Hall Institute of Medical Research, Melbourne, Australia,3Peter MacCallum Cancer Centre, Melbourne, Australia

摘要 Abstract

中文摘要
引言:大多数死于黑色素瘤的患者是在早期疾病复发后死亡。因此,迫切需要改进对高复发风险早期黑色素瘤患者的识别和管理。肿瘤微环境(TME)、亚克隆肿瘤细胞内在特征和细胞相互作用可能在黑色素瘤复发中发挥关键作用。空间转录组学(ST)最适于表征这些因素,并可能为克服早期黑色素瘤复发提供新见解和策略。 方法:我们检查了12份具有极端临床结局的早期(厚,T4b)FFPE原发性黑色素瘤样本,这些样本从前瞻性收集的Melanoma Research Victoria数据库中识别。其中,7例患者为T4b黑色素瘤,具有出乎意料的良好结局,即诊断后≤5年无复发;5例患者为T4b黑色素瘤,具有预期的不良结局,即诊断后≤5年复发(分别为晚期和早期复发组)。使用10X CytAssist Visium对样本进行探究,并在两组之间进行比较。进行了全面的生物信息学分析,包括用于初始点聚类的Bayespace和Harmony;用于簇注释的SingleR;用于细化簇识别的RCTD反卷积;对伪bulk计数的edgeR及差异表达基因(DEG)的基因集检验;用于差异细胞组成的sscomp;用于空间免疫-肿瘤结构分析的SPIAT,以及用于探究基因表达模式和相互作用区域的非负矩阵分解(NMF)和SpaceMarkers。 结果:每份样本中均揭示了关键细胞类型,包括肿瘤细胞、多样的免疫细胞亚群、成纤维细胞、巨噬细胞和角质形成细胞。包括真皮、表皮和侵袭性肿瘤前沿在内的组织结构得到了良好表征。DEG识别出在晚期组相较于早期组中SLC5A10、PFKFB2、FBXO32、GABRB3、SMIM38和CDH7下调。基因集分析揭示了在晚期组相较于早期组中标志性缺氧、血管生成、EMT、糖酵解、IL2、TNFa和TGFb通路上调。两组间细胞组成各异,晚期组的肿瘤纯度显著较低,免疫细胞丰度较高,高于早期组。NMF揭示了与肿瘤和免疫细胞相关的特定模式,在晚期组相较于早期组中,肿瘤与免疫细胞相互作用区域的IGHA2、CYP4X1、RBMXL3和AIRE显著下调。 结论:本研究是首批使用ST分析具有极端临床结局的原发性黑色素瘤样本的研究之一。我们的结果揭示,原发性黑色素瘤的细胞组成差异以及参与免疫激活、炎症和代谢的关键基因的差异表达,可能与黑色素瘤复发相关。
查看英文原文 English abstract
Introduction: Most patients that die from melanoma do so after recurrence of early stage disease. There is, therefore, an urgent need to improve the identification and management of patients with early stage melanoma at high risk of recurrence. The tumour microenvironment (TME), subclonal tumour cell intrinsic features and cellular interactions likely play key roles in melanoma recurrence. Spatial transcriptomics (ST) is optimally positioned to characterize these factors and may provide novel insights and strategies to overcome early stage melanoma recurrence. Methods: We examined 12 early stage (thick, T4b) FFPE primary melanoma samples with extreme clinical outcomes, identified from the prospectively collected Melanoma Research Victoria database. Of these, 7 patients had T4b melanoma with an unexpectedly good outcome of no recurrence ≤5 years of diagnosis and 5 patients had T4b melanoma with an expectedly poor outcome of recurrence ≤5 years of diagnosis (late and early recurrence groups, respectively). Samples were interrogated using 10X CytAssist Visium with comparisons between the two groups. Comprehensive bioinformatics analyses were performed including Bayespace and Harmony for initial spot clustering; SingleR for cluster annotation; RCTD deconvolution to refine cluster identification; edgeR on pseudo-bulk counts and gene set testing of differentially expressed genes (DEG); sscomp for differential cellular composition; SPIAT for spatial immune-tumor architecture analysis and non-negative matrix factorization (NMF) and SpaceMarkers for exploration of gene expression patterns and interacting regions. Results: Key cell types were revealed within each sample, including tumor cells, diverse immune cell subsets, fibroblasts, macrophages and keratinocytes. Tissue architecture including dermis, epidermis and invasive tumour front were well characterised. DEG identified downregulation of SLC5A10, PFKFB2, FBXO32, GABRB3, SMIM38 and CDH7 in the late group relative to the early group. Gene set analysis revealed upregulation of the hallmark hypoxia, angiogenesis, EMT, glycolysis, IL2, TNFa and TGFb pathways in the late relative to the early group. Cellular compositions varied across the two groups, with the late group having significantly lower tumour purity and higher abundance of immune cells than the early group. NMF revealed specific patterns associated with tumor and immune cells, with significant downregulation of IGHA2, CYP4X1, RBMXL3 and AIRE at the interacting region between tumor and immune cells in the late relative to the early group. Conclusion: This study is one of the first to analyze primary melanoma samples with extreme clinical outcomes using ST. Our results reveal that differences in cellular composition of primary melanomas as well as differential expression of key genes involved in immune activation, inflammation and metabolism may be associated with melanoma recurrence.
利益披露 Disclosure
P. Bhave, BMS Travel. GSK Travel, Other, Speaker. Novartis Travel, Other, Speaker. MSD Travel. M. Trussart, None.. A. T. Papenfuss, None. G. A. McArthur, Array/Pfizer Roche/Genetech Other, Reimbursement of trials costs to the Peter MacCallum Cancer Centre . Novartis, Bristol Myers Squibb. Other, Non-reimbursed advisor.

← 返回 AACR 2026 检索